As Amgen's Prolia Goes, So Goes The Market
This article was originally published in The Pink Sheet Daily
Wall Street analysts' reactions are mixed as to the meaning of an FDA advisory committee's mixed votes on Amgen's denosumab.
You may also be interested in...
The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.